China and Hong Kong should relax biotech listing rules, venture capitalist says

South China Morning PostEN 1 min read 100% complete by Yulu Ao,Julie ZhangMarch 5, 2026 at 11:59 AM
China and Hong Kong should relax biotech listing rules, venture capitalist says

AI Summary

short article 1 min

Venture capitalist Nisa Leung, speaking at China's annual political meetings, advocated for mainland China and Hong Kong to relax listing rules for biotechnology companies and lower takeover thresholds. Leung, a managing partner at Aulis Capital and a member of the CPPCC, believes this would capitalize on renewed foreign interest in the healthcare sector, which was highlighted in Premier Li Qiang's government work report. She pointed to the successful Hong Kong listing of Insilico Medicine as a positive example, but noted regulatory bottlenecks at the China Securities Regulatory Commission (CSRC) are slowing down new listings. Leung emphasized the importance of biopharmaceutical companies expanding overseas and Hong Kong's growing role as a capital center for AI and healthcare.

Keywords

biotechnology 90% listing rules 80% china 70% hong kong 70% venture capital 60% healthcare sector 60% regulatory bottlenecks 50% biopharmaceutical companies 50% takeover thresholds 40% artificial intelligence 40%

Sentiment Analysis

Positive
Score: 0.30

Source Transparency

Source
South China Morning Post
Classification Confidence
90%

This article was automatically classified using rule-based analysis.

Find Similar Articles

AI-Powered

Discover articles with similar content using semantic similarity analysis.